ECTRIMS 2025 — Interim data from the MS-DETECT study

At ECTRIMS 2025 (European Committee for Treatment and Research in Multiple Sclerosis), we presented interim data from the MS-DETECT study (NCT05816122).

This international study, supported by Sanofi, evaluates MSCopilot® Detect, our digital medical device designed to detect subtle signs of disability worsening related to multiple sclerosis (MS).

Preliminary data confirms the feasibility of home digital monitoring and the relevance of measured biomarkers — gait, vision, cognition, and dexterity — as indicators of disease progression in real-world conditions.